BriaCell Therapeutics Warrant expiring 2031 (BCTXL) Financials
Newest figures come from the 10-K for FY2026, filed Oct 28, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCTXL SEC filings page.
This page shows BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Loss-making operations consume cash while research spending expands, leaving financing activity central to how this business funds itself.
Cash conversion is weak but directionally clear: FY2026's net loss was$34.9M alongside operating cash flow of-$28.7M , so the accounting loss was accompanied by a similar cash requirement rather than being mostly noncash. That need coincided with R&D rising37.4% while ROA reached-148.0% , linking poor asset returns to an investment-heavy cost base.
FY2026 liabilities were
R&D was
Financial Health Signals
We do not publish a peer-relative financial health score for BriaCell Therapeutics Corp. Warrant expiring 2031, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
BriaCell Therapeutics Corp. Warrant expiring 2031 passes 1 of 5 computable financial strength tests (4 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
BriaCell Therapeutics Corp. Warrant expiring 2031 reported a net loss of $34.9M while operations used $28.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BriaCell Therapeutics Corp. Warrant expiring 2031 reported an operating loss of $36.1M against $30K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BriaCell Therapeutics Corp. Warrant expiring 2031 reported a net loss of $12.3M in Q4 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
BriaCell Therapeutics Corp. Warrant expiring 2031 earned -$1.24 per diluted share (EPS) in Q4 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q4 2026.
Not reported for Q4 2026.
Cash & Balance Sheet
BriaCell Therapeutics Corp. Warrant expiring 2031 recorded an outflow of $6.0M in free cash flow in Q4 2026, representing a cash shortfall after capex.
BriaCell Therapeutics Corp. Warrant expiring 2031 held $9.9M in cash as of Q4 2026; no long-term debt figure is on record for that period.
Not reported for Q4 2026.
Margins & Returns
BriaCell Therapeutics Corp. Warrant expiring 2031's quarterly ROE was -75.1% in Q4 2026: one quarter's net income over shareholder equity, not annualized. This is down 29.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 45.3 percentage points.
Not reported for Q4 2026.
Not reported for Q4 2026.
Not reported for Q4 2026.
Capital Allocation
BriaCell Therapeutics Corp. Warrant expiring 2031 invested $10.5M in research and development in Q4 2026. This represents an increase of 48.1% from the same quarter a year earlier. Against the prior quarter it is up 76.5%.
BriaCell Therapeutics Corp. Warrant expiring 2031 reported no capital expenditure in Q4 2026.
Not reported for Q4 2026.
BCTXL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $10.5M+48.1% | $6.0M+24.0% | $6.1M+6.5% | $6.7M+82.3% | $7.1M+61.4% | $4.8M-37.2% | $5.7M-31.2% | $3.7M-46.5% |
| SG&A Expenses | $2.0M+41.7% | $1.7M+9.0% | $1.5M-0.5% | $1.6M+10.2% | $1.4M+6.0% | $1.5M-3.4% | $1.5M-5.6% | $1.5M-9.6% |
| Operating Income | -$12.6Mn/m | -$7.6Mn/m | -$7.5Mn/m | -$8.3Mn/m | -$8.6M | -$6.3Mn/m | -$7.2Mn/m | -$5.2Mn/m |
| EBITDA | N/A | -$7.6Mn/m | -$7.5Mn/m | -$8.3Mn/m | N/A | -$6.3Mn/m | -$7.1Mn/m | -$5.1Mn/m |
| Interest Expense | N/A | $30K-19.9% | N/A | N/A | N/A | $37K | N/A | N/A |
| Net Income | -$12.3Mn/m | -$7.2Mn/m | -$7.2Mn/m | -$8.2Mn/m | -$8.1Mn/m | -$6.1M-457.1% | -$6.3Mn/m | -$5.8M-196.7% |
| EPS (Basic) | -$1.24 | -$0.99 | -$2.58 | -$4.35 | N/A | -$16.42 | -$23.31 | -$32.67 |
| EPS (Diluted) | -$1.24 | -$0.99 | -$2.58 | -$4.35 | N/A | -$16.42 | -$23.31 | -$32.67 |
| Diluted Shares (Avg) | N/A | 7M | 3M | 2M | N/A | 373,067 | 269,957 | 177,606 |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Income Tax.
BCTXL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $23.6M+8.9% | $27.1M+59.2% | $33.6M+258.8% | $13.1M+25.5% | $21.6M+268.7% | $17.0M+174.1% | $9.4M-23.4% | $10.4M-44.1% |
| Current Assets | $22.0M+10.6% | $25.4M+71.7% | $32.2M+349.3% | $11.3M+38.1% | $19.9M+445.4% | $14.8M+167.4% | $7.2M-39.0% | $8.2M-55.4% |
| Cash & Equivalents | $9.9M-6.1% | $6.9M-44.8% | $29.9M+496.4% | $2.7M-53.1% | $10.5M+1117.3% | $12.5M+1231.7% | $5.0M-19.7% | $5.8M-57.6% |
| Short-Term Investments | $10.7M+45.0% | $15.9Mn/m | $0n/m | $7.5Mn/m | $7.4Mn/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $7.2M+90.5% | $3.0M-34.3% | $2.7M-53.5% | $3.1M-51.4% | $3.8M-54.3% | $4.6M-62.3% | $5.8M-71.6% | $6.4M-59.9% |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | $4.3M-35.9% | $5.2M+33.3% | $5.0M+376.7% |
| Non-Current Liabilities | $39K-88.5% | $72K-90.2% | $195K-78.5% | $407K-76.2% | $338K-69.2% | $730K-87.1% | $906K-94.6% | $1.7M-88.6% |
| Total Equity | $16.4M-8.3% | $24.1M+93.8% | $30.9M+758.1% | $10.0M+146.8% | $17.9Mn/m | $12.4Mn/m | $3.6Mn/m | $4.0M+48.5% |
| Retained Earnings | -$146.7Mn/m | -$134.3Mn/m | -$127.2Mn/m | -$120.0Mn/m | -$111.8Mn/m | -$103.7Mn/m | -$97.5Mn/m | -$91.2Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Long-Term Investments, Goodwill, Long-Term Debt.
BCTXL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0Mn/m | -$7.0Mn/m | -$8.0Mn/m | -$7.7Mn/m | -$8.1Mn/m | -$7.2Mn/m | -$5.9Mn/m | -$7.0Mn/m |
| Depreciation & Amortization | $29K+27.8% | $29K+27.8% | $23K0.0% | $23K0.0% | $23K | $23K+498.5% | $23K+498.0% | $23K+498.2% |
| Stock-Based Compensation | N/A | N/A | $286K+0.3% | $295K+10.4% | N/A | $225K-42.7% | $285K-43.0% | $267K-50.0% |
| Capital Expenditures | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$6.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $5.0Mn/m | -$16.0Mn/m | $7.3Mn/m | -$75Kn/m | -$7.4Mn/m | -$105K | -$75K | -$75K |
| Financing Cash Flow | $3.9M-70.9% | $0-100.0% | N/A | N/A | $13.6M | $14.7M | $5.2M | $12.0M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BCTXL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q4'2610-K | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -75.1%-29.9pp | -29.8%+19.6pp | -23.4%+151.3pp | -82.2%+61.4pp | -45.3% | -49.4% | -174.6% | -143.5%-364.1pp |
| Return on Assets | -52.3%-14.9pp | -26.5%+9.6pp | -21.5%+45.7pp | -62.7%-7.0pp | -37.4%-16.7pp | -36.0%-63.7pp | -67.2%+25.1pp | -55.7%-87.9pp |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | 3.41+2.6x | 1.37-1.6x | 1.65-15.9x |
| Liabilities-to-Equity | 0.44+0.2x | 0.13-0.2x | 0.09-1.5x | 0.31-1.3x | 0.21 | 0.37 | 1.60 | 1.58-4.3x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Where BriaCell Therapeutics Corp. Warrant expiring 2031 Ranks
Frequently Asked Questions
No, BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported a net loss of $34.9M in fiscal year 2026.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had EBITDA of -$35.9M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has a return on equity of -212.8% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) recorded an outflow of $28.8M in free cash flow during fiscal year 2026. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) recorded an outflow of $28.7M in operating cash flow during fiscal year 2026, representing cash used by core business activities.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had $23.6M in total assets as of fiscal year 2026, including both current and long-term assets.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) invested $127K in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) invested $29.2M in research and development during fiscal year 2026.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had a liabilities-to-equity ratio of 0.44 as of fiscal year 2026, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2026, because the filing data we hold for that year carries no long-term debt figure.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) had a return on assets of -148.0% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) has a Piotroski F-Score of 1 out of 5 computable signals; 4 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported a net loss of $34.9M while operations used $28.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
BriaCell Therapeutics Corp. Warrant expiring 2031 (BCTXL) reported an operating loss of $36.1M against $30K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.